Literature DB >> 15893700

Morphine modulates chemokine gene regulation in normal human astrocytes.

Supriya D Mahajan1, Stanley A Schwartz, Ravikumar Aalinkeel, Ram P Chawda, Donald E Sykes, Madhavan P N Nair.   

Abstract

Chemokines and their receptors have been implicated in the pathogenesis of neuroAIDS. Herein we describe the effects of morphine on the gene expression of beta chemokines and their receptors by primary normal human astrocytes (NHA). Our results show that NHA treated with morphine showed significant downregulation of the gene expression of beta chemokines, MCP-1, and MIP-1 beta, while reciprocally upregulating the expression of their specific receptors, CCR2b, CCR3, and CCR5 as detected by real-time quantitative PCR. These morphine-induced effects on NHA cells were reversed by the opioid mu receptor antagonist, naloxone. Further, our results indicate that morphine-induced effects are mediated via the modulation of MAPK and CREB signaling pathways. These results support our hypothesis that opiates act as co-factors in the neuropathogenesis of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893700     DOI: 10.1016/j.clim.2005.02.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  47 in total

1.  Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophages.

Authors:  Jessica L Reynolds; Wing Cheung Law; Supriya D Mahajan; Ravikumar Aalinkeel; Bindukumar Nair; Donald E Sykes; Ken-Tye Yong; Rui Hui; Paras N Prasad; Stanley A Schwartz
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-12       Impact factor: 4.147

2.  CXCR4 signaling mediates morphine-induced tactile hyperalgesia.

Authors:  Natalie M Wilson; Hosung Jung; Matthew S Ripsch; Richard J Miller; Fletcher A White
Journal:  Brain Behav Immun       Date:  2010-12-28       Impact factor: 7.217

3.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila Keresztes; Jiyang Ren; William R Roeske; Todd W Vanderah; Eva V Varga
Journal:  J Neuroimmunol       Date:  2012-01-30       Impact factor: 3.478

Review 4.  Effects of opiates and HIV proteins on neurons: the role of ferritin heavy chain and a potential for synergism.

Authors:  Lindsay Festa; Olimpia Meucci
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 5.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 6.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

Review 7.  Neuronal chemokines: versatile messengers in central nervous system cell interaction.

Authors:  A H de Haas; H R J van Weering; E K de Jong; H W G M Boddeke; K P H Biber
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

8.  Chemokines and their receptors in intracerebral hemorrhage.

Authors:  Yao Yao; Stella E Tsirka
Journal:  Transl Stroke Res       Date:  2012-04-03       Impact factor: 6.829

9.  Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques.

Authors:  William D Cornwell; Mark G Lewis; Xiaoxuan Fan; Jay Rappaport; Thomas J Rogers
Journal:  J Neuroimmunol       Date:  2013-09-20       Impact factor: 3.478

10.  The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells.

Authors:  Randall L Davis; Daniel J Buck; Neda Saffarian; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2007-05-01       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.